What are Thrombolytic drugs?

Thrombolytic drugs are pharmacologic agents that share a common mechanism (typically targeting Fibrin). 0 are currently marketed, with 3 more in clinical development.

Thrombolytic

0 marketed 3 in Phase 3

This page covers all Thrombolytic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Fibrin, tPA, Plasminogen.

Targets

Fibrin · tPA · Plasminogen

Phase 3 pipeline (3)

CureXcell · Macrocure Ltd. · Cardiovascular
CureXcell is a recombinant human thrombolytic enzyme.
Standard-dose rtPA · The George Institute · Cardiovascular
Standard-dose rtPA works by dissolving blood clots to restore blood flow to the brain.
Recombinant human urokinase · Tasly Biopharmaceuticals Co., Ltd. · Cardiovascular
Recombinant human urokinase is a thrombolytic agent that works by activating plasminogen to plasmin, which then breaks down blood clots.